Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial

JACC: Cardiovascular Interventions

Volumn 9, Issue 17, 2016, Pages 1780-1789

  Gargiulo, Giuseppe ^a,b   Ariotti, Sara ^a,c   Santucci, Andrea ^a   Piccolo, Raffaele ^a   Baldo, Andrea ^a   Franzone, Anna ^a   Magnani, Giulia ^a   Marino, Marcello ^a   Esposito, Giovanni ^b   Windecker, Stephan ^a   Valgimigli, Marco ^a,c  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

bleeding; clopidogrel; DAPT; ischemic events; sex

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CREATININE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; WARFARIN; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; ASSESSMENT OF HUMANS; BARE METAL STENT; BARE METAL STENTING; BLEEDING; BLEEDING ACADEMIC RESEARCH CONSORTIUM CRITERIA; CARDIAC PATIENT; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CLINICAL OUTCOME; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DEATH; DISEASE SEVERITY; DRUG SAFETY; DUAL ANTIPLATELET THERAPY; EVEROLIMUS ELUTING CORONARY STENT; FEMALE; FOLLOW UP; HEALTH DISPARITY; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MULTICENTER STUDY; PACLITAXEL ELUTING CORONARY STENT; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; STENT THROMBOSIS; TREATMENT DURATION; ZOTAROLIMUS ELUTING CORONARY STENT; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; CORONARY THROMBOSIS; DEVICES; DIAGNOSTIC IMAGING; DRUG ADMINISTRATION; ITALY; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; NEOINTIMA; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; STENT; STROKE; TIME FACTOR; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; AGED; ASPIRIN; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; CORONARY THROMBOSIS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEMORRHAGE; HUMANS; ITALY; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NEOINTIMA; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; STENTS; STROKE; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84992322947     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2016.05.046     Document Type: Article

References (27)

1. 1 Peterson, E.D., Lansky, A.J., Kramer, J., Anstrom, K., Lanzilotta, M.J., Effect of gender on the outcomes of contemporary percutaneous coronary intervention. Am J Cardiol 88 (2001), 359–364.
2. 2 Lempereur, M., Magne, J., Cornelis, K., et al. Impact of gender difference in hospital outcomes following percutaneous coronary intervention. Results of the Belgian Working Group on Interventional Cardiology (BWGIC) registry. EuroIntervention 12 (2016), e216–e223.
3. 3 Benamer, H., Tafflet, M., Bataille, S., et al. Female gender is an independent predictor of in-hospital mortality after STEMI in the era of primary PCI: insights from the Greater Paris Area PCI Registry. EuroIntervention 6 (2011), 1073–1079.
4. 4 Lansky, A.J., Pietras, C., Costa, R.A., et al. Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation 111 (2005), 1611–1618.
5. 5 Duvernoy, C.S., Smith, D.E., Manohar, P., et al. Gender differences in adverse outcomes after contemporary percutaneous coronary intervention: an analysis from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) percutaneous coronary intervention registry. Am Heart J 159 (2010), 677–683.
6. 6 Stefanini, G.G., Kalesan, B., Pilgrim, T., et al. Impact of sex on clinical and angiographic outcomes among patients undergoing revascularization with drug-eluting stents. J Am Coll Cardiol Intv 5 (2012), 301–310.
7. 7 Lansky, A.J., Mehran, R., Cristea, E., et al. Impact of gender and antithrombin strategy on early and late clinical outcomes in patients with non-ST-elevation acute coronary syndromes (from the ACUITY trial). Am J Cardiol 103 (2009), 1196–1203.
8. 8 Mehilli, J., Kastrati, A., Dirschinger, J., Bollwein, H., Neumann, F.J., Schomig, A., Differences in prognostic factors and outcomes between women and men undergoing coronary artery stenting. JAMA 284 (2000), 1799–1805.
9. 9 Berger, J.S., Sanborn, T.A., Sherman, W., Brown, D.L., Influence of sex on in-hospital outcomes and long-term survival after contemporary percutaneous coronary intervention. Am Heart J 151 (2006), 1026–1031.
10. 10 Regueiro, A., Fernandez-Rodriguez, D., Brugaletta, S., et al. Sex-related impact on clinical outcome of everolimus-eluting versus bare-metal stents in ST-segment myocardial infarction. Insights from the EXAMINATION trial. Rev Esp Cardiol (Engl Ed) 68 (2015), 382–389.
11. 11 Valgimigli, M., Campo, G., Monti, M., et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 125 (2012), 2015–2026.
12. 12 Valgimigli, M., Ariotti, S., Costa, F., Duration of dual antiplatelet therapy after drug-eluting stent implantation: will we ever reach a consensus?. Eur Heart J 36 (2015), 1219–1222.
13. 13 Valgimigli, M., Costa, F., Byrne, R., Haude, M., Baumbach, A., Windecker, S., Dual antiplatelet therapy duration after coronary stenting in clinical practice: results of an EAPCI survey. EuroIntervention 11 (2015), 68–74.
14. 14 Navarese, E.P., Andreotti, F., Schulze, V., et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ, 350, 2015, h1618.
15. 15 Capodanno, D., Gargiulo, G., Buccheri, S., Giacoppo, D., Capranzano, P., Tamburino, C., Meta-analyses of dual antiplatelet therapy following drug-eluting stent implantation: do bleeding and stent thrombosis weigh similar on mortality?. J Am Coll Cardiol 66 (2015), 1639–1640.
16. 16 Giustino, G., Baber, U., Sartori, S., et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. J Am Coll Cardiol 65 (2015), 1298–1310.
17. 17 Palmerini, T., Benedetto, U., Bacchi-Reggiani, L., et al. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet 385 (2015), 2371–2382.
18. 18 Montalescot, G., Brieger, D., Dalby, A.J., Park, S.J., Mehran, R., Duration of dual antiplatelet therapy after coronary stenting: a review of the evidence. J Am Coll Cardiol 66 (2015), 832–847.
19. 19 Valgimigli, M., Campo, G., Percoco, G., et al. Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention: design and rationale for the Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY). Am Heart J 160 (2010), 804–811.
20. 20 Bonaca, M.P., Bhatt, D.L., Cohen, M., et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 372 (2015), 1791–1800.
21. 21 Tomey, M.I., Mehran, R., Brener, S.J., et al. Sex, adverse cardiac events, and infarct size in anterior myocardial infarction: an analysis of intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction (INFUSE-AMI). Am Heart J 169 (2015), 86–93.
22. 22 Khera, S., Kolte, D., Gupta, T., et al. Temporal trends and sex differences in revascularization and outcomes of ST-segment elevation myocardial infarction in younger adults in the United States. J Am Coll Cardiol 66 (2015), 1961–1972.
23. 23 Koskinas, K.C., Raber, L., Zanchin, T., et al. Clinical impact of gastrointestinal bleeding in patients undergoing percutaneous coronary interventions. Circulation Cardiovasc Interv, 8, 2015, e002053.
24. 24 Ducrocq, G., Wallace, J.S., Baron, G., et al. Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis. Eur Heart J 31 (2010), 1257–1265.
25. 25 Mauri, L., Kereiakes, D.J., Yeh, R.W., et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371 (2014), 2155–2166.
26. 26 Collet, J.P., Silvain, J., Barthelemy, O., et al. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. Lancet 384 (2014), 1577–1585.
27. 27 Lee, C.W., Ahn, J.M., Park, D.W., et al. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial. Circulation 129 (2014), 304–312.